logo-loader
viewCircassia Pharmaceuticals PLC

Block listing Interim Review

/**/ sup{font-size:80%} .g{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.g{}p.am{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.ak{font-size:14.0pt;font-family:"Arial","sans-serif"}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.ai{font-size:10.0pt;font-family:"Arial","sans-serif"}span.ah{font-size:10.0pt;font-family:"Arial","sans-serif"; font-variant:small-caps}p.an{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:12.0pt;text-autospace:none}span.ag{font-size:8.0pt;font-family:"Arial","sans-serif"}p.ao{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold} table.ap{width:451.3pt;margin-left:-5.4pt;border-collapse:collapse;border:none}td.ac{width:49.86%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.aq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm}td.ab{width:50.14%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.aa{width:49.86%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.y{width:50.14%;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.z{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}td.x{width:37.18%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.w{width:12.68%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.v{width:19.0%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.u{width:8.44%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.t{width:22.7%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.ar{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:0cm;text-align:justify}span.s{font-size:10.0pt; font-family:"Arial","sans-serif"}span.q{font-family: "Arial","sans-serif"; font-size: 10.0pt; text-decoration: underline}span.p{font-size: 10.0pt;font-family:"Arial","sans-serif"}td.o{border:none}p.as{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt; margin-left:0cm}br.l{page-break-before:always}td.k{width:49.84%;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} td.j{width:50.16%;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.i{width:49.84%;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.h{width:50.16%;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} /**/
RNS Number : 3559M
Circassia Pharmaceuticals Plc
13 September 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 13 September 2019

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia EMI Share Option Scheme

Period of return:

From:

1st January 2019

To:

30th June 2019

Balance of unallotted securities under scheme(s) from previous return:

700,750

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

700,750

         

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2007 Unapproved Share Scheme

Period of return:

From:

1st January 2019

To:

30th June 2019

Balance of unallotted securities under scheme(s) from previous return:

203,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

-

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

203,000

         

 

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2014 Performance Share Plan Scheme

Period of return:

From:

1st January 2019

To:

30th June 2019

Balance of unallotted securities under scheme(s) from previous return:

83,414

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

(6,738)

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

76,676

         

 

Name of applicant:

Circassia Pharmaceuticals plc

Name of scheme:

Circassia 2015 Performance Share Plan Scheme

Period of return:

From:

1st January 2019

To:

30th June 2019

Balance of unallotted securities under scheme(s) from previous return:

305,628

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

(25,016)

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

280,612

         

 

  

 

Name of contact:

Julien Cotta

Telephone number of contact:

01865 405 560

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BLRGGUAABUPBGQW

Quick facts: Circassia Pharmaceuticals PLC

Price: 16.25

Market: LSE
Market Cap: £60.97 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

2 weeks, 4 days ago

RNS

Holding(s) in Company

1 week, 3 days ago

Director/PDMR Shareholding

1 week, 6 days ago

Total Voting Rights

2 weeks ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

3 weeks, 5 days ago